Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Person › Details

Bernd Sommer (Boehringer Ingelheim (Group))

Sommer, Bernd (Boehringer Ingelheim 201312 Head of Neuroscience Research)

 

Organisation Organisation Boehringer Ingelheim (Group)
Products Product drug discovery
  Product 2 CNS drug
     

Boehringer Ingelheim. (12/18/13). "Press Release: Circuit Therapeutics and Boehringer Ingelheim Announce Signature of a Research Partnership Agreement to Discover New Approaches to Treating Psychiatric Disorders". Menlo Park, CA & Ingelheim.

Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors. Circuit Therapeutics' key technology, optogenetics, allows the control of individual nerve cells and circuits within the brain enabling their functional identification and characterization. The combination of optogenetics and sophisticated molecular technologies provides an unprecedented level of focus to identify novel drug targets and approaches for drug development. The new insights enabled by circuit-based analysis provide fundamentally differentiated approaches to understanding and treating brain disorders, which have otherwise been difficult to address.

Under the terms of the agreement the research and development capabilities of the two companies will be brought together to provide novel avenues for drug discovery in a three-year research program. Further details of the agreement are not disclosed.

"We are excited to work with Boehringer Ingelheim to utilize Circuit's unique capabilities to advance drug discovery. The innovative and ambitious vision and passion of Boehringer Ingelheim to make a difference in the area of neuropsychiatric disease treatments combined with Circuit's innovative technologies makes an ideal partnership. We look forward to a highly productive research collaboration that will provide transformational drugs to impact patients' lives," said Fred Moll, Chairman of Circuit Therapeutics.

"We are very enthusiastic about being able to work in a partnership with Circuit Therapeutics, one of the leading organizations in the field of circuit biology and optogenetics", said Dr. Bernd Sommer, the head of neuroscience research at Boehringer Ingelheim. "We believe that, by working together to investigate maladaptive brain circuitry with this exciting approach, we will be able to obtain a better understanding of the neurobiological basis of human neuropsychiatric disorders, thereby allowing us to make a difference to science, disease and patients."


About Circuit Therapeutics

Circuit Therapeutics is a privately held discovery stage biotechnology company based in Menlo Park, California. The company's cutting edge technologies focused on neural circuits are being applied to enable new ways of drug discovery and development of direct therapeutic interventions across a broad range of indications.


About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.boehringer-ingelheim.com


Media contact

Dr Reinhard Malin
Binger Strasse 173
55216 Ingelheim am Rhein

GERMANY
Phone + 49 - 6132 - 77 90815
Fax + 49 - 6132 - 77 6601

Boehringer Ingelheim US (for US media enquiries)
Sperry Mylott
Senior Associate Director, U.S. Corporate Communications
(203) 798-4630
sperry.mylott@boehringer-ingelheim.com

Circuit Therapeutics
Dr. Karoly Nikolich
President and Founder
1505 O'Brien Drive
Menlo Park, California 94025
Tel. (650) 543-1401
knikolich@circuittx.com

   
Record changed: 2018-12-04

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px


More documents for Bernd Sommer


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top